文献速递淋巴瘤

大剂量甲氨蝶呤用于超高危大B细胞淋巴瘤中枢预防的国际多中心分析

High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis.
PubMed 文献 · J Clin Oncol · 2026-06-11

该国际多中心回顾性分析合并两项既往研究数据,纳入1,923例符合超高危标准的大B细胞淋巴瘤患者,比较使用与未使用大剂量甲氨蝶呤(HD-MTX)者的中枢神经系统复发率。结果显示两组3年中枢复发率无显著差异,各超高危亚组亦未见获益。

要点

  • 超高危大B细胞淋巴瘤患者中,HD-MTX未显著降低3年中枢复发率。
  • 孤立性中枢复发分析及6个月里程碑分析均未显示HD-MTX获益。
  • 数据不支持对多数超高危患者常规使用HD-MTX作中枢预防。

核心结论

  • 在全部超高危患者及任一单个亚组中,HD-MTX均未显著降低中枢神经系统复发。
  • 数据强烈支持既往研究提示HD-MTX预防对多数患者无有意义获益。

研究设计与样本

  • 两项既往回顾性分析数据合并,形成超高危患者队列,按是否使用HD-MTX分组比较。
  • 超高危标准为满足以下至少一项:CNS国际预后指数评分5-6;睾丸、肾/肾上腺或乳腺受累;≥3个结外部位。
  • 共分析1,923例符合超高危标准的患者,未用HD-MTX组1,051例,用HD-MTX组872例。
  • 主要结局为自诊断起计算的中枢复发率(孤立或伴全身复发),并对6个月无进展的缓解患者做里程碑分析。

主要发现

  • 3年中枢复发率:未用HD-MTX组9.3%对比HD-MTX组8.1%,校正风险比1.13(95%CI 0.82至1.57)。
  • 仅限孤立性中枢复发的分析亦无差异:5.9%对比5.7%,校正风险比1.03(95%CI 0.69至1.53)。
  • 里程碑分析(未用HD-MTX组782例,用HD-MTX组773例)3年中枢复发为6.7%对比6.6%,校正风险比0.95(95%CI 0.62至1.44)。

临床怎么用

  • 对于具超高危特征的大B细胞淋巴瘤患者,不应期待HD-MTX带来显著的中枢复发下降。
  • 临床决策可结合个体情况权衡HD-MTX的获益与风险。

局限性

  • 为回顾性分析,存在其固有局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In large B-cell lymphoma (LBCL), use of high-dose methotrexate (HD-MTX) to prevent CNS relapse (so-called CNS prophylaxis) remains controversial. International guidelines continue to recommend HD-MTX in patients deemed ultra high risk (UHR) because of a lack of robust data specific to these subgroups. This study was designed to examine the impact of HD-MTX specifically in UHR patients. METHODS: Data from two previous retrospective analyses were combined to produce a cohort of UHR patients (≥1 of the following criteria: CNS international prognostic index score 5-6; testicular, renal/adrenal, or breast involvement; ≥3 extranodal sites), treated with or without HD-MTX. The primary outcome was CNS relapse rate (isolated or concurrent with systemic relapse) measured from diagnosis with additional landmark analysis of all responding patients with no progression event at 6 months. RESULTS: Analyses were performed on 1,923 patients meeting UHR criteria. No significant difference in 3-year CNS relapse rate was observed between no HD-MTX (n = 1,051) versus HD-MTX patients (n = 872), including in multivariable analyses adjusting for baseline characteristics (3-year rate, 9.3% v 8.1%; adjusted hazard ratio [HR], 1.13 [95% CI, 0.82 to 1.57]). Analyses restricted to isolated CNS relapse also confirmed no difference (5.9% v 5.7%; adjusted HR, 1.03 [95% CI, 0.69 to 1.53]). In the landmark analysis (no HD-MTX n = 782, HD-MTX n = 773), no difference in 3-year CNS relapse was observed (6.7% v 6.6%, adjusted HR, 0.95 [95% CI, 0.62 to 1.44]). CONCLUSION: To our knowledge, this is the largest international comparative data set of patients with LBCL with UHR features showing no significant reduction in CNS relapse with HD-MTX in all UHR or in any individual subgroup. Despite inherent limitations of retrospective analyses, the data strongly support previous studies in suggesting HD-MTX prophylaxis has no meaningful benefit for most patients.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Wilson MR, Lewis KL, Kirkwood AA, et al. High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis. J Clin Oncol. 2026. PMID: 42274647. doi:10.1200/JCO-26-00947

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。